Creatinol O-Phosphate

Last Updated: September 28 2022

Creatinol O-Phosphate (COP) is a creatine analogue synthesized for the treatment of heart complications. It appears to protect cardiac cells at 3g injections, but does not have sufficient evidence for oral consumption.

dosageDosage

Creatinol O-Phosphate is most often used for

Summary

Creatinol O-Phosphate (COP) is a synthetic analogue of creatine that was created as a cardioprotective drug, and it appears to be helpful against arrythmia and aid the integrity of cardiac tissue following injections of up to three grams. Via this method of administration and dosage, it appears to be safe as well as effective.

A lack of information exists on COP oral ingestion and whether the benefits translate from oral to injections. Additionally, all research appears to be a few decades old and has since just ceased for unknown reasons; a weird thing for such a promising compound (unless another cardioprotective agent was deemed safer and more effective, making injections of COP for clinical usage not needed to be researched anymore).

Due to the lack of pharmacokinetic data, it is hard to ascertain the benefits associated with COP ingestion. If absorbed, it will be cardioprotective and safe. Optimal dosing regimen is not known at this time due to no bioavailability data.

For all intents and purposes, COP supplementation should be viewed as completely different as creatine supplementation. Even after COP loses the phosphorus group, it metabolizes into creatinol and not creatine.

What else is Creatinol O-Phosphate known as?
Note that Creatinol O-Phosphate is also known as:
  • COP
  • Creatinolphosphate
  • Aplodan
Creatinol O-Phosphate should not be confused with:
Dosage information

Past studies used injections of up to 3g daily. There is currently no bioavailability data on how much is absorbed, but if it is 100% then this is the dose where benefits have been noted in humans.

Supplements Demystified: Get Our Unbiased, Evidence-Based Guide

Don't miss out on the latest research

References
3.^Godfraind T, Sturbois XThe prevention by creatinol O-phosphate of myocardial lesions evoked by isoprenalineArch Int Pharmacodyn Ther.(1979 Feb)
6.^Knippel M, Bana G, Pusterla GLEffects of creatinol O-phosphate on serum enzymes in acute myocardial infarctionArzneimittelforschung.(1979)
8.^Cadel A, Palumbo A, Zerilli G, Pria R, Fanciulli R, Conversano S, Galbiati RAntiarrhythmic effectiveness of creatinol O-phosphate in manArzneimittelforschung.(1979)
10.^Melloni GF, Minoja GM, Lureti GF, Merlo L, Pamparana F, Brusoni BAcute clinical tolerance of creatinol O-phosphateArzneimittelforschung.(1979)